Nature Communications (Jun 2021)

Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors

  • Marcel A. Schneider,
  • Michael Linecker,
  • Ralph Fritsch,
  • Urs J. Muehlematter,
  • Daniel Stocker,
  • Bernhard Pestalozzi,
  • Panagiotis Samaras,
  • Alexander Jetter,
  • Philipp Kron,
  • Henrik Petrowsky,
  • Claude Nicolau,
  • Jean-Marie Lehn,
  • Bostjan Humar,
  • Rolf Graf,
  • Pierre-Alain Clavien,
  • Perparim Limani

DOI
https://doi.org/10.1038/s41467-021-24069-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 12

Abstract

Read online

Restoring oxygenation in hypoxic tumors might lead to favorable oncological outcome of patients if combined with standard multimodal therapy regimens. Here the authors report a phase Ib clinical trial of anti-hypoxic myo-inositol trispyrophosphate (ITPP) in hepato-pancreato-biliary neoplasms.